KCM
VRDN icon

Kynam Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Kynam Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$119M Buy
6,453,877
+4,112,225
+176% +$66.3M 6.55% 6
2026
Q1 		$45.8M Buy
2,341,652
+871,111
+59% +$25.9M 2.83% 10
2025
Q4 		$45.8M Sell
1,470,541
-2,957,386
-67% -$81.1M 2.92% 8
2025
Q3 		$95.6M Hold
4,427,927
– – 7.11% 6
2025
Q2 		$61.9M Sell
4,427,927
-272,073
-6% -$3.69M 6.66% 7
2025
Q1 		$63.4M Buy
4,700,000
+1,373,738
+41% +$23.4M 5.32% 7
2024
Q4 		$63.8M Buy
3,326,262
+814,967
+32% +$17.7M 3.77% 10
2024
Q3 		$57.1M Buy
2,511,295
+761,295
+44% +$12.4M 4.38% 10
2024
Q2 		$22.8M Buy
1,750,000
+1,616,123
+1,207% +$22.4M 1.76% 14
2024
Q1 		$2.34M Sell
133,877
-474,038
-78% -$9.19M 0.25% 23
2023
Q4 		$13.2M Sell
607,915
-91,766
-13% -$1.45M 1.47% 17
2023
Q3 		$10.7M Sell
699,681
-9,817
-1% -$187K 1.76% 14
2023
Q2 		$16.9M Buy
709,498
+165,895
+31% +$4.26M 2.32% 13
2023
Q1 		$13.8M Sell
543,603
-491,094
-47% -$15.7M 1.79% 16
2022
Q4 		$30.2M Buy
1,034,697
+34,697
+3% +$799K 4.64% 6
2022
Q3 		$20.5M Buy
1,000,000
+409,857
+69% +$7.37M 4.32% 7
2022
Q2 		$6.83M Buy
590,143
+317
+0.1% +$4.26K 1.74% 14
2022
Q1 		$10.9M Buy
589,826
+301,892
+105% +$5.8M 3.54% 10
2021
Q4 		$5.69M Buy
+287,934
New +$5.36M 3.04% 11

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Kynam Capital Management's VRDN Position: Q2 2026 in Review

Kynam Capital Management increased its Viridian Therapeutics (VRDN) stake by 176% in Q2 2026, buying an estimated $66.3M and bringing the position to 6,453,877 shares worth $119M. The position accounts for 6.55% of the portfolio, ranked #6.

Kynam Capital Management first reported a position in VRDN in Q4 2021 and has held it in 19 quarters since. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Kynam Capital Management held 6,453,877 shares of Viridian Therapeutics worth $119M as of Q2 2026.
  • Kynam Capital Management bought 4,112,225 Viridian Therapeutics shares in Q2 2026, an estimated $66.3M.
  • Viridian Therapeutics made up 6.55% of Kynam Capital Management's portfolio in Q2 2026, its #6 holding.
  • Kynam Capital Management first reported a position in Viridian Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Kynam Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.